OKI-179

October, 2020

Initial Results from a Phase 1 trial of OKI-179, an Oral Class 1-selective Depsipeptide HDCA Inhibitor, in Patients with Advanced Solid Tumors

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics. 24 October – 25 October 2020


October, 2019

OKI-179, A 1st in Class, Orally Administered HDAC Inhibitor with a Romidepsin-like Profile

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics. 25 October – 30 October 2019


August, 2019

Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas

Cancer Immunol Res: 7(8) August 2019. doi: 10.118/2236-6066. CIR-18-0875


June, 2019

Could inhibiting both HDAC and PD-1 improve immuno-oncology treatments?

NEWS Provided by Fierce Biotech